Do Patients Want MASLD Screening? Hepatology | February 2026

Screening for metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly discussed, but concerns about anxiety, stigma, and overdiagnosis persist. This population-based study from Olmsted County evaluated how individuals perceive the benefits and harms of proactive MASLD screening.

Among 461 screened participants (74% survey response rate), psychological impact was modest. Only 14% reported screening-related anxiety, and 14% were concerned about disclosing a potential diagnosis. Reassurance was substantial: 99% of participants without MASLD felt reassured about their liver health, 48% reported improved quality of life, and 25% adopted healthier lifestyle behaviours.

Among 77 individuals diagnosed with MASLD, 52% experienced some anxiety; however, 95% believed early diagnosis was important to prevent cirrhosis, and 97% valued cardiovascular risk mitigation. Importantly, 79% reported the diagnosis motivated healthier habits, and 30% achieved >10% weight loss following screening.

Overall, perceived benefits—including awareness, lifestyle change, and early prevention—outweighed psychological harms.

Conclusion: Patient-centred MASLD screening appears acceptable and potentially empowering, supporting early detection strategies integrated with structured lifestyle interventions.